Evaluation of antitumor and toxic side effects of mitomycin C-estradiol conjugates

International Journal of Pharmaceutics

Volumn 279, Issue 1-2, 2004, Pages 81-93

  Ishiki, Nobuyuki ^a   Onishi, Hiraku ^a   MacHida, Yoshiharu ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Antitumor and toxic side effect; Body weight; Leukocyte number; Mitomycin C estradiol conjugate; Tumor growth

Indexed keywords

ANTINEOPLASTIC AGENT; ESTRADIOL; ESTRADIOL BENZOATE; MITOMYCIN C; PROPYLENE GLYCOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CANCER GROWTH; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFECT; DRUG FORMULARY; FEMALE; LETHAL DOSE; LEUKOCYTE COUNT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTRADIOL; FEMALE; LEUKOCYTE COUNT; MALE; MICE; MITOMYCIN; SARCOMA 180; TISSUE DISTRIBUTION;

EID: 3242756519     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2004.04.017     Document Type: Article

References (25)

1. Benz C., Cadman E., Gwin J., Wu T., Amara J., Eisenfeld A., Daaies P. Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro. Cancer Res. 43:1983;5298-5303
2. Brigger I., Chaminade P., Marsaud V., Appel M., Besnard M., Gurny R., Renoir M., Couvreur P. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int. J. Pharm. 214:2001;37-42
3. Buzdar A.U., Hortobagyi G.N. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J. Clin. Oncol. 16:1998;348-353
4. Chawla J.S., Amiji M.M. Biodegradable poly(ε-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int. J. Pharm. 249:2002;127-138
5. Ellmen J., Werner D., Hakulinen P., Keiling R., Fargeot P., Falkson G., Bezwoda W.R. Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients. Cancer Chemother. Pharmacol. 45:2000;402-408
6. Fujita H. Pharmacokinetics of mitomycin C and its derivative KW-2083. Jpn. J. Cancer Chemother. 9:1982;1362-1373
7. Futamura Y., Matsumoto K. Characteristics of peripheral blood monocytes and bone marrow macrophages from rats treated with mitomycin C, 5-fluorouracil or phenylhydradine. J. Toxicol. Sci. 20:1995;1-7
8. Ishiki N., Onishi H., Machida Y. Conversion characteristics of the conjugates of mitomycin C with estradiol and estradiol benzoate in various pH media. Chem. Pharm. Bull. 45:1997a;1345-1349
9. Ishiki N., Onishi H., Machida Y. Biological properties of conjugates of mitomycin C with estradiol benzoate and estradiol: their stability characteristics in biological media and their binding abilities to estrogen receptor. Biol. Pharm. Bull. 20:1997b;1096-1102
10. Ishiki N., Onishi H., Machida Y. In vivo properties of the conjugates of mitomycin C with estradiol benzoate and estradiol: pharmacokinetics and antitumor characteristics against P388 leukemia and sarcoma 180,. Biol. Pharm. Bull. 21:1998;1180-1186
11. Ishiki, N., Onishi, H., Machida, Y., 2002. Antitumor activities of conjugates of mitomycin C with estradiol benzoate and estradiol via glutaric acid in suspension dosage form. Biol. Pharm. Bull. 25, 1373-1377.
12. Jimbow K., Miura S., Ito Y., Kasuga T., Ito S. Utilization of melanin precursors for experimental chemotherapy of malignant melanoma. Jpn. J. Cancer Chemother. 11:1984;2125-2132
13. Kasiotis K.M., Magiatis P., Pratsinis H., Skaltsounis A.-L., Abadji V., Charalambous A., Moutsatsou P., Haroutounian S.A. Synthesis and biological evaluation of novel daunorubicin-estrogen conjugates. Steroids. 66:2001;785-791
14. Kobayashi T., Inaba M., Tsukagoshi S., Sakurai Y., Imai R., Morimoto M. Comparison of the hematologic toxicity of 7-N-(p-hydroxyphenyl)-mitomycin C and mitomycin C. GANN. 72:1981;950-954
15. Kuduk S.D., Harris C.R., Zheng F.F., Stepp-Lorenzino L., Querfelli Q., Rosen N., Danishefsky S.J. Synthesis and evaluation of geldanamycin-testosterone hybrids. Bioorg. Med. Chem. Lett. 10:2000;1303-11306
16. Malet C., Gompel A., Spritzer P., Bricout N., Yaneva H., Mowszowicz I., Kuttenn F., Mauvais-Jarvis P. Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture. Cancer Res. 48:1988;7193-7199
17. Mittelman A., Shukla S.K., Murphy G.P. Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate. J. Urol. 115:1976;409-412
18. Ohsawa N., Yamazaki Z., Isurugi K. Bestrabucil: a possible target-oriented anticancer agent. Jpn. J. Cancer Chemother. 11:1984;2115-2124
19. Ozaki M., Matsuda M., Muramatsu S. Antitumor effect of estramustine phosphate disodium (EMP) in mice. Jpn. Pharmacol. Ther. 8:1980;3707-3710
20. Sutherland R.L., Murphy L.C., Foo M.S., Green M.D., Whybourne M., Krozowski Z.S. High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature. 288:1980;273-275
21. Takakura Y., Takagi A., Hashida M., Sezaki H. Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 4:1987;293-300
22. Tamura F., Sakauchi K., Asano Y., Enomoto S., Hota T., Fujita H. Concentration of KM2210 (bestrabucil) in plasma, tumor and other tissues in tumor-bearing mice - concentration in plasma and tissues and antitumor characteristics in Walker 256-bearing mice, and their correlation to number of peripheral white blood cells. Clin. Rep. 20:1986;1835-1846
23. Tokunaga Y., Iwasa T., Fujisaki J., Sawai S., Kagayama A. Liposomal sustained-release delivery systems for intravenous injection. III. Antitumor activity of lipophilic mitomycin C prodrug-bearing liposomes. Chem. Pharm. Bull. 36:1988;3565-3573
24. Varga, J.M., 1985. Hormone-drug conjugates. In: Widder, K.J., Green, R. (Eds.), Methods in Enzymology, vol. 112. Academic Press, New York, pp. 25-269.
25. Wada T., Asano K., Enomoto S., Hota T. Binding characteristics of KM2210 (bestrabucil) and its metabolites to the estrogen receptor. Clin. Rep. 20:1986;1985-1988